Canada is recognized globally for its world-leading obesity care guidelines — yet Canadians continue to struggle to access the very treatment plans we’ve developed. Meanwhile, the same model of care is now the one the World Health Organization (WHO) is urging other countries to adopt.
The WHO recently released its first ever guideline on anti-obesity medications, reinforcing a chronic disease model of care that Canadian experts have championed for years.
WHO’s stance mirrors the Canadian framework laid out in 2020 clinical guidelines: obesity is a chronic, relapsing disease that requires comprehensive, lifelong care — the kind that includes timely diagnosis, trained providers, co-ordination among the various health professionals involved, mental-health support, and — when appropriate — pharmacotherapy and bariatric surgery.
